Shattuck Labs Announces Two Poster Presentations At UEG Week 2026
Presentation Details
Format: Moderated poster presentation
Title: Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA) Targeting Bispecific Antibody
Presenter: Mahmud Hussain, Ph.D., Director, R&D of Shattuck Labs
Date/Time: October 19, 2026; 1:00–2:00 p.m. CEST
Format: ePoster presentation
Title: Soluble TL1A/Anti-TL1A Immune Complexes Induce De Novo Production of TL1A and Induce Anti-Drug Antibodies That Cross-Bind Approved IBD Antibodies
Presenter: Suresh de Silva, Ph.D., Chief Scientific Officer of Shattuck Labs
Date/Time: October 17–20, 2026 (available for viewing throughout the congress)
The posters will be available under Events & Presentations in the Investor Relations section of the Company's website at following the congress.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck's expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: .
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment